News Room
Technophage has been granted with the ‘COTEC Innovative Status 2026’
Technophage is proud to announce that it has recently been granted with the ‘COTEC Innovative Status 2026’. COTEC Portugal is the main Portuguese…
Technophage Receives Regulatory Approval to Initiate Phase 1/2a TP-122 Clinical Study in Europe
We are pleased to share an important milestone for Technophage: the Phase 1/2a clinical study TP-122_101A has recently received the necessary…
Technophage Recognized as PME Líder 2025
Once more we are thrilled to announce that Technophage has been recognized by IAPMEI, I.P. – Agência para a Competitividade e Inovação with the PME…
Pipeline
Invest in our products
GMP manufacturing
Learn more about GMP manufacturing
Technophage
Who we are, What we do
Therapeutic
areas
Technophage is committed to the development of biological and chemical products for infection, neurosciences and ophthalmology